1IA
TARS icon

1620 Investment Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

1620 Investment Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Sell
1,721
-63
-4% -$4.03K 0.07% 244
2026
Q1 		$125K Sell
1,784
-23
-1% -$1.61K 0.08% 210
2025
Q4 		$148K Sell
1,807
-3
-0.2% -$224 0.1% 188
2025
Q3 		$108K Sell
1,810
-25
-1% -$1.23K 0.07% 223
2025
Q2 		$74.3K Buy
+1,835
New +$82.6K 0.05% 266

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

1620 Investment Advisors's TARS Position: Q2 2026 in Review

1620 Investment Advisors reduced its Tarsus Pharmaceuticals (TARS) stake by 3.5% in Q2 2026, selling an estimated $4.03K and leaving 1,721 shares worth $108K. The position accounts for 0.07% of the portfolio, ranked #244.

1620 Investment Advisors first reported a position in TARS in Q2 2025 and has held it in 5 quarters since. The position peaked at $148K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • 1620 Investment Advisors held 1,721 shares of Tarsus Pharmaceuticals worth $108K as of Q2 2026.
  • 1620 Investment Advisors sold 63 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $4.03K.
  • Tarsus Pharmaceuticals made up 0.07% of 1620 Investment Advisors's portfolio in Q2 2026, its #244 holding.
  • 1620 Investment Advisors first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 1620 Investment Advisors's Tarsus Pharmaceuticals position peaked at $148K in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.